{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:10:32Z","timestamp":1786864232707,"version":"build-2736575974"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10787-026-02186-6","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:19:08Z","timestamp":1774570748000},"page":"2923-2971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topoisomerase I\/II inhibitors: from established drugs to next-generation therapeutics"],"prefix":"10.1007","volume":"34","author":[{"given":"Pinky","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivank","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stalin","family":"Arulsamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2186_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104255","volume":"104","author":"EM Abbass","year":"2020","unstructured":"Abbass EM, Khalil AK, Mohamed MM, Eissa IH, El-Naggar AM (2020) Quinoxalines as Topo II inhibitors. Bioorg Chem 104:104255","journal-title":"Bioorg Chem"},{"issue":"1","key":"2186_CR2","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41598-024-56313-w","volume":"14","author":"ME Adly","year":"2024","unstructured":"Adly ME, Gedawy EM, El-Malah AA, Khalil OM (2024) Design, synthesis and in vitro anticancer activity of new lomefloxacin derivatives. Sci Rep 14(1):6175","journal-title":"Sci Rep"},{"issue":"8","key":"2186_CR3","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.bmc.2016.03.017","volume":"24","author":"P Ahmad","year":"2016","unstructured":"Ahmad P, Woo H, Jun KY, Kadi AA, Abdel-Aziz HA, Kwon Y, Rahman AM (2016) ATP-competitive Topo II\u03b1 catalytic inhibitors. Bioorg Med Chem 24(8):1898\u20131908","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"2186_CR4","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","volume":"9","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Kolb-Sielecki J, Safina SZ, Xue X, Jamieson BD (2022) Avatrombopag in thrombocytopenia. Lancet Haematol 9(3):e179\u2013e189","journal-title":"Lancet Haematol"},{"issue":"5","key":"2186_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/ph14050399","volume":"14","author":"LH Al-Wahaibi","year":"2021","unstructured":"Al-Wahaibi LH, Amer AA, Marzouk AA, Gomaa HA, Youssif BG, Abdelhamid AA (2021) Ciprofloxacin derivatives as gyrase\/Topo IV inhibitors. Pharmaceuticals 14(5):399","journal-title":"Pharmaceuticals"},{"key":"2186_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1419242","volume":"12","author":"LH Al-Wahaibi","year":"2024","unstructured":"Al-Wahaibi LH, Mahmoud MA, Alzahrani HA, Abou-Zied HA, Gomaa HA, Youssif BG, Br\u00e4se S, Rabea SM (2024) Schiff bases targeting gyrase\/Topo IV. Front Chem 12:1419242","journal-title":"Front Chem"},{"issue":"7","key":"2186_CR7","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1021\/acs.jmedchem.9b01760","volume":"63","author":"JM Arencibia","year":"2020","unstructured":"Arencibia JM, Brindani N, Franco-Ulloa S, Nigro M, Kuriappan JA, Ottonello G, Bertozzi SM, Summa M, Girotto S, Bertorelli R, Armirotti A (2020) Novel topoisomerase II poisons. J Med Chem 63(7):3508\u20133521","journal-title":"J Med Chem"},{"issue":"4","key":"2186_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/mol.119.117259","volume":"96","author":"M Atwal","year":"2019","unstructured":"Atwal M, Swan RL, Rowe C, Lee KC, Lee DC, Armstrong L, Cowell IG, Austin CA (2019) Intercalating TOPII poisons. Mol Pharmacol 96(4):475\u2013484","journal-title":"Mol Pharmacol"},{"issue":"7","key":"2186_CR9","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1021\/cr200325f","volume":"112","author":"C Bailly","year":"2012","unstructured":"Bailly C (2012) Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy. Chem Rev 112(7):3611\u20133640","journal-title":"Chem Rev"},{"issue":"4","key":"2186_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2174\/1568011054222364","volume":"5","author":"EL Baldwin","year":"2005","unstructured":"Baldwin EL, Osheroff N (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5(4):363\u2013372","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"24","key":"2186_CR11","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.3390\/molecules30244760","volume":"30","author":"\u0141 Balewski","year":"2025","unstructured":"Balewski \u0141, Kornicka A (2025) Recent advances in synthetic isoquinoline-based derivatives in drug design. Molecules 30(24):4760","journal-title":"Molecules"},{"issue":"2","key":"2186_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6020051","volume":"6","author":"D Bedi","year":"2019","unstructured":"Bedi D, Henderson HJ, Manne U, Samuel T (2019) Camptothecin-induced PD-L1 expression. Medicines 6(2):51","journal-title":"Medicines"},{"issue":"28","key":"2186_CR13","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.2174\/0929867325666180306165725","volume":"25","author":"K Bergant","year":"2018","unstructured":"Bergant K, Jane\u017ei\u010d M, Perdih A (2018) Bioassays and in silico methods in the identification of human DNA topoisomerase II\u03b1 inhibitors. Curr Med Chem 25(28):3286\u20133318","journal-title":"Curr Med Chem"},{"issue":"7","key":"2186_CR14","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1021\/acs.jcim.0c00202","volume":"60","author":"K Bergant Loboda","year":"2020","unstructured":"Bergant Loboda K, Janezic M, \u0160tampar M, \u017degura B, Filipi\u010d M, Perdih A (2020) Bithiazoles as Topo II\u03b1 catalytic inhibitors. J Chem Inf Model 60(7):3662\u20133678","journal-title":"J Chem Inf Model"},{"issue":"2","key":"2186_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L (2022) Treatment landscape of triple-negative breast cancer. Nat Rev Clin Oncol 19(2):91\u2013113","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2186_CR16","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1093\/nar\/gkab142","volume":"49","author":"PR Bianco","year":"2021","unstructured":"Bianco PR, Lu Y (2021) Single-molecule insight into stalled replication fork rescue in Escherichia coli. Nucleic Acids Res 49(8):4220\u20134238","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2186_CR17","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","volume":"78","author":"J Boshuizen","year":"2020","unstructured":"Boshuizen J, Peeper DS (2020) Rational cancer treatment combinations: An urgent clinical need. Mol Cell 78(6):1002\u20131018","journal-title":"Mol Cell"},{"issue":"5","key":"2186_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ph17050598","volume":"17","author":"M Bo\u021ba","year":"2024","unstructured":"Bo\u021ba M, Vlaia L, J\u00eejie AR, Marcovici I, Cri\u015fan F, Oancea C, Dehelean CA, Mateescu T, Moac\u0103 EA (2024) Synergistic interactions in lung cancer therapy. Pharmaceuticals 17(5):598","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2186_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tibs.2023.11.001","volume":"49","author":"KW Caldecott","year":"2024","unstructured":"Caldecott KW (2024) Causes and consequences of DNA single-strand breaks. Trends Biochem Sci 49(1):68\u201378","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"2186_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM (2024) Anthracycline cardiotoxicity. JACC CardioOncol 6(5):655\u2013677","journal-title":"JACC CardioOncol"},{"key":"2186_CR21","volume":"25","author":"C Cattrini","year":"2020","unstructured":"Cattrini C, Capaia M, Boccardo F, Barboro P (2020) Etoposide in prostate cancer. Cancer Treat Res Commun 25:100221","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"2186_CR22","first-page":"13359","volume":"9","author":"UA Cevik","year":"2024","unstructured":"Cevik UA, Kaya B, Celik I, Rudrapal M, Rakshit G, Karayel A, Levent S, Osmaniye D, Sa\u011fl\u0131k \u00d6zkan BN, Baysal M, Atl\u0131 Eklioglu O (2024) Benzimidazole-triazole Topo I inhibitors. ACS Omega 9(11):13359\u201313372","journal-title":"ACS Omega"},{"key":"2186_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-biochem-061809-100002","volume":"82","author":"SH Chen","year":"2013","unstructured":"Chen SH, Chan NL, Hsieh TS (2013) Mechanistic insights into DNA topoisomerases. Annu Rev Biochem 82:139\u2013170","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"2186_CR24","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1016\/j.arabjc.2016.06.014","volume":"12","author":"TC Chen","year":"2019","unstructured":"Chen TC, Yu DS, Chen SJ, Chen CL, Lee CC, Hsieh YY, Chang LC, Guh JH, Lin JJ, Huang HS (2019) Tetracyclic azafluorenones as Topo I inhibitors. Arab J Chem 12(8):4348\u20134364","journal-title":"Arab J Chem"},{"issue":"3","key":"2186_CR25","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/ijms23031701","volume":"23","author":"W Choi","year":"2022","unstructured":"Choi W, Lee ES (2022) Targeting DNA damage response in cancer. Int J Mol Sci 23(3):1701","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2186_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11864-023-01175-z","volume":"25","author":"V Costanzo","year":"2024","unstructured":"Costanzo V, Ratre YK, Andretta E, Acharya R, Bhaskar LVKS, Verma HK (2024) Cancer drug\u2013induced cardiotoxicity in blood cancer patients. Curr Treat Options Oncol 25(4):465\u2013495","journal-title":"Curr Treat Options Oncol"},{"key":"2186_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ijbiomac.2019.07.097","volume":"138","author":"FA da Silva Filho","year":"2019","unstructured":"da Silva Filho FA, de Freitas Souza T, Ribeiro AG, Alves JEF, de Oliveira JF, de Lima Souza TRC, de Moura RO, de Lima MDCA, de Carvalho Junior LB, de Almeida SMV (2019) Acridine-thiosemicarbazone interaction studies. Int J Biol Macromol 138:582\u2013589","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"2186_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1128\/MMBR.00020-08","volume":"72","author":"MS Dillingham","year":"2008","unstructured":"Dillingham MS, Kowalczykowski SC (2008) RecBCD enzyme and repair of double-stranded DNA breaks. Microbiol Mol Biol Rev 72(4):642\u2013671","journal-title":"Microbiol Mol Biol Rev"},{"issue":"36","key":"2186_CR29","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.2174\/1381612825666190112164211","volume":"24","author":"J Dini\u0107","year":"2018","unstructured":"Dini\u0107 J, Podolski-Reni\u0107 A, Jeremi\u0107 M, Pe\u0161i\u0107 M (2018) Potential of natural-based anticancer compounds for P-glycoprotein inhibition. Curr Pharm des 24(36):4334\u20134354","journal-title":"Curr Pharm des"},{"issue":"20","key":"2186_CR30","doi-asserted-by":"publisher","first-page":"12711","DOI":"10.1021\/acs.chemrev.6b00191","volume":"116","author":"AC Drohat","year":"2016","unstructured":"Drohat AC, Coey CT (2016) Role of base excision \u201crepair\u201d enzymes in erasing epigenetic marks from DNA. Chem Rev 116(20):12711\u201312729","journal-title":"Chem Rev"},{"issue":"10","key":"2186_CR31","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/pro.4171","volume":"30","author":"A Duprey","year":"2021","unstructured":"Duprey A, Groisman EA (2021) Regulation of DNA supercoiling across evolution. Protein Sci 30(10):2042\u20132056","journal-title":"Protein Sci"},{"key":"2186_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","volume":"166","author":"MJ Edelman","year":"2022","unstructured":"Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng CQ, Bentsion D, Chouaid C (2022) Dinutuximab with irinotecan. Lung Cancer 166:135\u2013142","journal-title":"Lung Cancer"},{"issue":"11","key":"2186_CR33","doi-asserted-by":"publisher","first-page":"1900123","DOI":"10.1002\/ardp.201900123","volume":"352","author":"IH Eissa","year":"2019","unstructured":"Eissa IH, Metwaly AM, Belal A, Mehany AB, Ayyad RR, El-Adl K, Mahdy HA, Taghour MS, El-Gamal KM, El-Sawah ME, Elmetwally SA (2019) New quinoxalines as DNA intercalators and Topo II inhibitors. Arch Pharm 352(11):1900123","journal-title":"Arch Pharm"},{"key":"2186_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104399","volume":"105","author":"K El-Adl","year":"2020","unstructured":"El-Adl K, El-Helby AGA, Sakr H, Elwan A (2020) Triazoloquinoxaline derivatives. Bioorg Chem 105:104399","journal-title":"Bioorg Chem"},{"issue":"1","key":"2186_CR35","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/s41598-023-30885-5","volume":"13","author":"MA Elanany","year":"2023","unstructured":"Elanany MA, Osman EEA, Gedawy EM, Abou-Seri SM (2023) Fluoroquinolone Analogs. Sci Rep 13(1):4144","journal-title":"Sci Rep"},{"issue":"1","key":"2186_CR36","doi-asserted-by":"publisher","first-page":"2157825","DOI":"10.1080\/14756366.2022.2157825","volume":"38","author":"MF El-Behairy","year":"2023","unstructured":"El-Behairy MF, Abd-Allah WH, Khalifa MM, Nafie MS, Saleh MA, Abdel-Maksoud MS, Al-Warhi T, Eldehna WM, Al-Karmalawy AA (2023) Dibenzoazepines as Topo II inhibitors. J Enzyme Inhib Med Chem 38(1):2157825","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"2186_CR37","doi-asserted-by":"publisher","first-page":"2242714","DOI":"10.1080\/14756366.2023.2242714","volume":"38","author":"S El-Kalyoubi","year":"2023","unstructured":"El-Kalyoubi S, Khalifa MM, Abo-Elfadl MT, El-Sayed AA, Elkamhawy A, Lee K, Al-Karmalawy AA (2023) Spirooxindole dual Topo I\/II inhibitors. J Enzyme Inhib Med Chem 38(1):2242714","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2186_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103492","volume":"94","author":"SA El-Metwally","year":"2020","unstructured":"El-Metwally SA, Khalil AK, El-Sayed WM (2020) Thienopyrimidine Topo II inhibitors. Bioorg Chem 94:103492","journal-title":"Bioorg Chem"},{"key":"2186_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.inoche.2024.112028","volume":"161","author":"S Fathi-Karkan","year":"2024","unstructured":"Fathi-Karkan S, Qindeel M, Arshad R, Moafian Z, Ghazy E, Rahdar A, Ghotekar S (2024) Irinotecan-loaded nanomaterials. Inorg Chem Commun 161:112028","journal-title":"Inorg Chem Commun"},{"issue":"13","key":"2186_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS (2024) Overcoming drug resistance in cancer cells. Cancers 16(13):2478","journal-title":"Cancers"},{"issue":"23","key":"2186_CR41","doi-asserted-by":"publisher","first-page":"11422","DOI":"10.1039\/D2NJ01646J","volume":"46","author":"MM Hammoud","year":"2022","unstructured":"Hammoud MM, Nageeb AS, Morsi MA, Gomaa EA, Elmaaty AA, Al-Karmalawy AA (2022) Cyclopentaquinoline derivatives. New J Chem 46(23):11422\u201311436","journal-title":"New J Chem"},{"issue":"1","key":"2186_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/ol.2022.13628","volume":"25","author":"M Hassan","year":"2022","unstructured":"Hassan M, Trung V, Bedi D, Shaddox S, Gunturu D, Yates C, Datta P, Samuel T (2022) PD-L1 modulation after Topo inhibition. Oncol Lett 25(1):41","journal-title":"Oncol Lett"},{"key":"2186_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.104920","volume":"112","author":"HA Hofny","year":"2021","unstructured":"Hofny HA, Mohamed MF, Gomaa HA, Abdel-Aziz SA, Youssif BG, El-Koussi NA, Aboraia AS (2021) Quinoline hybrids targeting gyrase. Bioorg Chem 112:104920","journal-title":"Bioorg Chem"},{"issue":"6","key":"2186_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061218","volume":"13","author":"KCY Huang","year":"2021","unstructured":"Huang KCY, Chiang SF, Yang PC, Ke TW, Chen TW, Hu CH, Huang YW, Chang HY, Chen WTL, Chao KC (2021) Immunogenic cell death by Topo I inhibitor TLC388. Cancers Basel 13(6):1218","journal-title":"Cancers Basel"},{"issue":"9","key":"2186_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098457","volume":"24","author":"JY Jang","year":"2023","unstructured":"Jang JY, Kim D, Kim ND (2023) Combination chemotherapy with topoisomerase inhibitors. Int J Mol Sci 24(9):8457","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2186_CR46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/ijms26020796","volume":"26","author":"JY Jang","year":"2025","unstructured":"Jang JY, Kim D, Im E, Kim ND (2025) Etoposide in lung cancer. Int J Mol Sci 26(2):796","journal-title":"Int J Mol Sci"},{"key":"2186_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.chphi.2024.100479","volume":"8","author":"RD Jawarkar","year":"2024","unstructured":"Jawarkar RD, Khan AN, Bhagat DR, Khatale PN, Burakale PV, Farooqui S, Mali SN (2024) Pyrrolo-benzimidazole quinones as TOPII\u03b2 inhibitors. Chem Phys Impact 8:100479","journal-title":"Chem Phys Impact"},{"issue":"8","key":"2186_CR48","first-page":"1217","volume":"97","author":"G Joshi","year":"2020","unstructured":"Joshi G, Kumar R (2020) Anticancer activity of imidazole-fused quinoxalines via human topoisomerase inhibition. J Indian Chem Soc 97(8):1217\u20131225","journal-title":"J Indian Chem Soc"},{"issue":"1","key":"2186_CR49","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","volume":"15","author":"DC Joshi","year":"2024","unstructured":"Joshi DC, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K, Tuli HS, Gupta M (2024) Novel therapeutic agents in clinical trials. Disc Oncol 15(1):342","journal-title":"Disc Oncol"},{"key":"2186_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103629","volume":"99","author":"M Kadagathur","year":"2020","unstructured":"Kadagathur M, Devi GP, Grewal P, Sigalapalli DK, Makhal PN, Banerjee UC, Bathini NB, Tangellamudi ND (2020) Diindoloazepinone Topo I inhibitors. Bioorg Chem 99:103629","journal-title":"Bioorg Chem"},{"issue":"11","key":"2186_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02527-x","volume":"41","author":"M Kamle","year":"2024","unstructured":"Kamle M, Pandhi S, Mishra S, Barua S, Kurian A, Mahato DK, Rasane P, B\u00fcsselberg D, Kumar P, Calina D, Sharifi-Rad J (2024) Camptothecin and its derivatives. Med Oncol 41(11):263","journal-title":"Med Oncol"},{"key":"2186_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105174","volume":"115","author":"RA Kardile","year":"2021","unstructured":"Kardile RA, Sarkate AP, Borude AS, Mane RS, Lokwani DK, Tiwari SV, Azad R, Burra PV, Thopate SR (2021) Quinoline derivatives as Topo I inhibitors. Bioorg Chem 115:105174","journal-title":"Bioorg Chem"},{"key":"2186_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00994","volume":"9","author":"S Kaur","year":"2019","unstructured":"Kaur S, Schwartz AL, Jordan DG, Soto-Pantoja DR, Kuo B, Elkahloun AG, Griner LM, Thomas CJ, Ferrer M, Thomas A, Tang SW (2019) Schlafen-11 and sensitivity to Topo inhibitors. Front Oncol 9:994","journal-title":"Front Oncol"},{"issue":"1","key":"2186_CR54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12885-021-07823-7","volume":"21","author":"S Kawai","year":"2021","unstructured":"Kawai S, Takeshima N, Hayasaka Y, Notsu A, Yamazaki M, Kawabata T, Yamazaki K, Mori K, Yasui H (2021) Irinotecan vs oxaliplatin meta-analysis. BMC Cancer 21(1):116","journal-title":"BMC Cancer"},{"issue":"9","key":"2186_CR55","doi-asserted-by":"publisher","first-page":"935","DOI":"10.4155\/fmc-2018-0472","volume":"11","author":"A Kolari\u010d","year":"2019","unstructured":"Kolari\u010d A, Novak D, Weiss M, Hrast M, Zdovc I, Anderluh M, Minovski N (2019) Bacterial topoisomerase inhibitors. Future Med Chem 11(9):935\u2013945","journal-title":"Future Med Chem"},{"issue":"4","key":"2186_CR56","first-page":"1689","volume":"62","author":"B Kundu","year":"2019","unstructured":"Kundu B, Das SK, Chowdhuri SP, Pal S, Sarkar D, Ghosh A, Mukherjee A, Bhattacharya D, Das BB, Talukdar A (2019) Quinoline Topo I poisons. J Med Chem 62(4):1689\u20131705","journal-title":"J Med Chem"},{"key":"2186_CR57","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.2147\/JIR.S329401","volume":"14","author":"B Lawal","year":"2021","unstructured":"Lawal B, Kuo YC, Sumitra MR, Wu AT, Huang HS (2021) Pharmacokinetics of HH-N25. J Inflamm Res 14:4901\u20134913","journal-title":"J Inflamm Res"},{"issue":"7","key":"2186_CR58","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1021\/acsinfecdis.8b00375","volume":"5","author":"L Li","year":"2019","unstructured":"Li L, Okumu AA, Nolan S, English A, Vibhute S, Lu Y, Hervert-Thomas K, Seffernick JT, Azap L, Cole SL, Shinabarger D (2019) 1,3-Dioxane-linked bacterial topoisomerase inhibitors. ACS Infect Dis 5(7):1115\u20131128","journal-title":"ACS Infect Dis"},{"issue":"8","key":"2186_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082876","volume":"21","author":"AL Li","year":"2020","unstructured":"Li AL, Hao Y, Wang WY, Liu QS, Sun Y, Gu W (2020) Indole derivatives of ursolic acid as Topo II inhibitors. Int J Mol Sci 21(8):2876","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2186_CR60","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.tcb.2024.01.009","volume":"34","author":"H Li","year":"2024","unstructured":"Li H, Playter C, Das P, McCord RP (2024) Chromosome compartmentalization. Trends Cell Biol 34(9):707\u2013727","journal-title":"Trends Cell Biol"},{"issue":"4","key":"2186_CR61","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1007\/s11033-019-04605-0","volume":"46","author":"A Macieja","year":"2019","unstructured":"Macieja A, Kopa P, Galita G, Pastwa E, Majsterek I, Poplawski T (2019) Topo II inhibitors with DNA repair blockers. Mol Biol Rep 46(4):3625\u20133636","journal-title":"Mol Biol Rep"},{"issue":"4","key":"2186_CR62","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41419-024-06653-2","volume":"15","author":"F Marrocco","year":"2024","unstructured":"Marrocco F, Falvo E, Mosca L, Tisci G, Arcovito A, Reccagni A, Limatola C, Bernardini R, Ceci P, D\u2019Alessandro G, Colotti G (2024) Nose-to-Brain Drug Delivery. Cell Death Dis 15(4):262","journal-title":"Cell Death Dis"},{"issue":"6","key":"2186_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/17460441.2022.2055545","volume":"17","author":"E Martin-Encinas","year":"2022","unstructured":"Martin-Encinas E, Selas A, Palacios F, Alonso C (2022) The design and discovery of topoisomerase I inhibitors as anticancer therapies. Expert Opin Drug Discov 17(6):581\u2013601","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"2186_CR64","doi-asserted-by":"publisher","first-page":"553","DOI":"10.13005\/bpj\/2396","volume":"15","author":"S Mastrangelo","year":"2022","unstructured":"Mastrangelo S, Attina G, Triarico S, Romano A, Maurizi P, Ruggiero A (2022) DNA topoisomerase inhibitors in cancer therapy. Biomed Pharmacol J 15(2):553\u2013562","journal-title":"Biomed Pharmacol J"},{"issue":"1","key":"2186_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010094","volume":"16","author":"VM Matias-Barrios","year":"2023","unstructured":"Matias-Barrios VM, Dong X (2023) Topoisomerase II inhibitors in synthetic lethality. Pharmaceuticals 16(1):94","journal-title":"Pharmaceuticals"},{"key":"2186_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.633142","volume":"10","author":"VM Matias-Barrios","year":"2021","unstructured":"Matias-Barrios VM, Radaeva M, Song Y, Alperstein Z, Lee AR, Schmitt V, Lee J, Ban F, Xie N, Qi J, Lallous N (2021) Catalytic Topo II inhibitors. Front Oncol 10:633142","journal-title":"Front Oncol"},{"issue":"1","key":"2186_CR67","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.molcel.2023.11.014","volume":"84","author":"L Milano","year":"2024","unstructured":"Milano L, Gautam A, Caldecott KW (2024) DNA damage and transcription stress. Mol Cell 84(1):70\u201379","journal-title":"Mol Cell"},{"issue":"10","key":"2186_CR68","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/antibiotics9100695","volume":"9","author":"EM Mohi El-Deen","year":"2020","unstructured":"Mohi El-Deen EM, Abd El-Meguid EA, Karam EA, Nossier ES, Ahmed MF (2020) Pyridothienopyrimidines as bacterial Topo II inhibitors. Antibiotics 9(10):695","journal-title":"Antibiotics"},{"issue":"15","key":"2186_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153819","volume":"13","author":"C Molinaro","year":"2021","unstructured":"Molinaro C, Martoriati A, Cailliau K (2021) Proteins from the DNA damage response: regulation, dysfunction, and anticancer strategies. Cancers 13(15):3819","journal-title":"Cancers"},{"issue":"19","key":"2186_CR70","doi-asserted-by":"publisher","first-page":"14590","DOI":"10.3390\/ijms241914590","volume":"24","author":"C Molinaro","year":"2023","unstructured":"Molinaro C, Wambang N, Pellegrini S, Henry N, Lensink MF, Germain E, Bousquet T, De Ruyck J, Cailliau K, P\u00e9linski L, Martoriati A (2023) Indenoisoquinoline copper derivative as a Topo I inhibitor. Int J Mol Sci 24(19):14590","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2186_CR71","doi-asserted-by":"publisher","first-page":"2205043","DOI":"10.1080\/14756366.2023.2205043","volume":"38","author":"MA Mourad","year":"2023","unstructured":"Mourad MA, Abo Elmaaty A, Zaki I, Mourad AA, Hofni A, Khodir AE, Aboubakr EM, Elkamhawy A, Roh EJ, Al-Karmalawy AA (2023) Dual Topo II\/EGFR inhibitors. J Enzyme Inhib Med Chem 38(1):2205043","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2186_CR72","first-page":"87","volume":"2","author":"N Nagar","year":"2011","unstructured":"Nagar N, Jat RK, Saharan R, Verma S, Sharma D (2011) Podophyllotoxin and glycosidic derivatives. Pharmacophore 2:87\u201397","journal-title":"Pharmacophore"},{"key":"2186_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104134","volume":"103","author":"MT Nemr","year":"2020","unstructured":"Nemr MT, AboulMagd AM (2020) Fused pyrimidines as Topo II inhibitors. Bioorg Chem 103:104134","journal-title":"Bioorg Chem"},{"issue":"10","key":"2186_CR74","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","volume":"7","author":"NY Ngoi","year":"2021","unstructured":"Ngoi NY, Pham MM, Tan DS, Yap TA (2021) Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer 7(10):930\u2013957","journal-title":"Trends Cancer"},{"issue":"19","key":"2186_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910247","volume":"25","author":"KC Nitiss","year":"2024","unstructured":"Nitiss KC, Bandak A, Berger JM, Nitiss JL (2024) Genome instability induced by topoisomerase misfunction. Int J Mol Sci 25(19):10247","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2186_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032532","volume":"24","author":"CO Okoro","year":"2023","unstructured":"Okoro CO, Fatoki TH (2023) A mini review of novel topoisomerase II inhibitors as future anticancer agents. Int J Mol Sci 24(3):2532","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2186_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43046-022-00126-3","volume":"34","author":"AA Omar","year":"2022","unstructured":"Omar AA, Basiouny L, Elnoby AS, Zaki A, Abouzid M (2022) St. Jude total therapy studies. J Egypt Natl Canc Inst 34(1):25","journal-title":"J Egypt Natl Canc Inst"},{"issue":"15","key":"2186_CR78","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/1759-7714.14527","volume":"13","author":"M Omori","year":"2022","unstructured":"Omori M, Noro R, Seike M, Matsuda K, Hirao M, Fukuizumi A, Takano N, Miyanaga A, Gemma A (2022) ABCB1\/ABCG2 resistance to Topo inhibitors. Thorac Cancer 13(15):2142\u20132151","journal-title":"Thorac Cancer"},{"issue":"21","key":"2186_CR79","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1021\/acs.jmedchem.0c00774","volume":"63","author":"JA Ortega","year":"2020","unstructured":"Ortega JA, Arencibia JM, Minniti E, Byl JAW, Franco-Ulloa S, Borgogno M, Genna V, Summa M, Bertozzi SM, Bertorelli R, Armirotti A (2020) Selective Topo II\u03b1 inhibitors. J Med Chem 63(21):12873\u201312886","journal-title":"J Med Chem"},{"issue":"6","key":"2186_CR80","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1080\/07391102.2020.1743365","volume":"39","author":"S Parveen","year":"2021","unstructured":"Parveen S, Arjmand F, Zhang Q, Ahmad M, Khan A, Toupet L (2021) Cu(II) complex as Topo I inhibitor. J Biomol Struct Dyn 39(6):2092\u20132105","journal-title":"J Biomol Struct Dyn"},{"issue":"11","key":"2186_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17111414","volume":"17","author":"HU P\u00e9rez-Ortega","year":"2025","unstructured":"P\u00e9rez-Ortega HU, C\u00f3rdova-Esp\u00edritu RR, Cano-Serrano S, Garc\u00eda-Gonz\u00e1lez E, Bravo-S\u00e1nchez MG, Orozco-Mosqueda MD, Jim\u00e9nez-Islas H, Luna-B\u00e1rcenas G, Villase\u00f1or-Ortega F (2025) Camptothecin in cancer therapy: current challenges and emerging strategies with nanoemulsions. Pharmaceutics 17(11):1414","journal-title":"Pharmaceutics"},{"issue":"5","key":"2186_CR82","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","volume":"17","author":"Y Pommier","year":"2010","unstructured":"Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17(5):421\u2013433","journal-title":"Chem Biol"},{"issue":"8","key":"2186_CR83","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1089\/ars.2012.4877","volume":"18","author":"VA Rao","year":"2013","unstructured":"Rao VA (2013) Iron chelators with topoisomerase-inhibitory activity and their anticancer applications. Antioxid Redox Signal 18(8):930\u2013955","journal-title":"Antioxid Redox Signal"},{"key":"2186_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2019.110725","volume":"199","author":"FV Rocha","year":"2019","unstructured":"Rocha FV, Farias RL, Lima MA, Batista VS, Nascimento-Junior NM, Garrido SS, Leopoldino AM, Goto RN, Oliveira AB, Beck J, Landvogt C (2019) Pd(II) complexes as Topo II\u03b1 inhibitors. J Inorg Biochem 199:110725","journal-title":"J Inorg Biochem"},{"issue":"23","key":"2186_CR85","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01411-19","volume":"93","author":"RM Rodr\u00edguez Stewart","year":"2019","unstructured":"Rodr\u00edguez Stewart RM, Berry JT, Berger AK, Yoon SB, Hirsch AL, Guberman JA, Patel NB, Tharp GK, Bosinger SE, Mainou BA (2019) Reovirus with Topo inhibitors. J Virol 93(23):e01128-19","journal-title":"J Virol"},{"issue":"1","key":"2186_CR86","doi-asserted-by":"publisher","first-page":"45","DOI":"10.21775\/cimb.031.045","volume":"31","author":"S Saha","year":"2019","unstructured":"Saha S, Chowdhury SR, Majumder HK (2019) DNA topoisomerases of kinetoplastid parasites: brief overview and recent perspectives. Curr Issues Mol Biol 31(1):45\u201362","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"2186_CR87","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/14756366.2018.1507029","volume":"34","author":"K Sangpheak","year":"2019","unstructured":"Sangpheak K, Mueller M, Darai N, Wolschann P, Suwattanasophon C, Ruga R, Chavasiri W, Seetaha S, Choowongkomon K, Kungwan N, Rungnim C (2019) Computational screening of chalcones acting against topoisomerase II\u03b1 and their cytotoxicity towards cancer cell lines. J Enzyme Inhib Med Chem 34(1):134\u2013143","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"6","key":"2186_CR88","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/13543776.2021.1879051","volume":"31","author":"A Selas","year":"2021","unstructured":"Selas A, Martin-Encinas E, Fuertes M, Masdeu C, Rubiales G, Palacios F, Alonso C (2021) Patent review of topoisomerase I inhibitors. Expert Opin Ther Pat 31(6):473\u2013508","journal-title":"Expert Opin Ther Pat"},{"issue":"4","key":"2186_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040680","volume":"16","author":"NK Sharma","year":"2024","unstructured":"Sharma NK, Bahot A, Sekar G, Bansode M, Khunteta K, Sonar PV, Hebale A, Salokhe V, Sinha BK (2024) Cancer defense against topoisomerase-active drugs. Cancers 16(4):680","journal-title":"Cancers"},{"key":"2186_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2018.03.033","volume":"79","author":"A Shrestha","year":"2018","unstructured":"Shrestha A, Park S, Shin S, Kadayat TM, Bist G, Katila P, Kwon Y, Lee ES (2018) SAR of phenol-pyridine derivatives. Bioorg Chem 79:1\u201318","journal-title":"Bioorg Chem"},{"issue":"3","key":"2186_CR91","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","volume":"63","author":"Z Skok","year":"2019","unstructured":"Skok Z, Zidar N, Kikelj D, Ila\u0161 J (2019) Dual Topo II inhibitors. J Med Chem 63(3):884\u2013904","journal-title":"J Med Chem"},{"issue":"12","key":"2186_CR92","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202209125","volume":"222","author":"TN Soliman","year":"2023","unstructured":"Soliman TN, Keifenheim D, Parker PJ, Clarke DJ (2023) Cell cycle responses to topoisomerase II inhibition. J Cell Biol 222(12):e202209125","journal-title":"J Cell Biol"},{"key":"2186_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112459","volume":"200","author":"Y Song","year":"2020","unstructured":"Song Y, Feng S, Feng J, Dong J, Yang K, Liu Z, Qiao X (2020) Pyrazoline\u2013indole derivatives targeting Topo II. Eur J Med Chem 200:112459","journal-title":"Eur J Med Chem"},{"key":"2186_CR94","doi-asserted-by":"publisher","first-page":"101371","DOI":"10.1016\/j.rechem.2024.101371","volume":"7","author":"GLS Sousa","year":"2024","unstructured":"Sousa GLS, da Silva Hon\u00f3rio T, de Souza Furtado P, Simon A, Cabral LM, Pereira GRC, Alves JEF, de Almeida SMV, Silva VR, de Souza Santos L, Bezerra DP (2024) Acridine-thiosemicarbazone derivatives as Topo II\u03b1 inhibitors. Results Chem 7:101371","journal-title":"Results Chem"},{"issue":"1","key":"2186_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2023.105423","volume":"17","author":"MR Sumitra","year":"2024","unstructured":"Sumitra MR, Chen LC, Tsai WC, Ansar M, Lawal B, Mokgautsi N, Guh JH, Wu ATH, Huang HS (2024) Thiochromenoquinoline derivatives. Arab J Chem 17(1):105423","journal-title":"Arab J Chem"},{"issue":"12","key":"2186_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0313278","volume":"19","author":"C Sun","year":"2024","unstructured":"Sun C, Fan E, Huang L, Zhang Z (2024) Second-line treatment for colorectal cancer. PLoS ONE 19(12):e0313278","journal-title":"PLoS ONE"},{"issue":"1","key":"2186_CR97","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/14756366.2022.2136172","volume":"38","author":"HK Swedan","year":"2023","unstructured":"Swedan HK, Kassab AE, Gedawy EM, Elmeligie SE (2023) Ciprofloxacin derivatives targeting Topo II. J Enzyme Inhib Med Chem 38(1):118\u2013137","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"6","key":"2186_CR98","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2174\/1568009622666220224110538","volume":"22","author":"BA Teicher","year":"2022","unstructured":"Teicher BA, Morris J (2022) Antibody\u2013drug conjugates. Curr Cancer Drug Targets 22(6):463\u2013529","journal-title":"Curr Cancer Drug Targets"},{"issue":"7","key":"2186_CR99","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamaoncol.2022.0514","volume":"8","author":"D Tripathy","year":"2022","unstructured":"Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Di\u00e9ras V, M\u00fcller V, Du Y, Currie SL (2022) Etirinotecan pegol in breast cancer. JAMA Oncol 8(7):1047\u20131052","journal-title":"JAMA Oncol"},{"issue":"16","key":"2186_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168492","volume":"22","author":"B Tyli\u0144ska","year":"2021","unstructured":"Tyli\u0144ska B, Dobosz A, Spycha\u0142a J, Cwynar-Zaj\u0105c \u0141, Czy\u017cnikowska \u017b, Ku\u017aniarski A, G\u0119barowski T (2021) Olivacine derivatives and Topo II. Int J Mol Sci 22(16):8492","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2186_CR101","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrm831","volume":"3","author":"JC Wang","year":"2002","unstructured":"Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3(6):430\u2013440","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2186_CR102","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1172\/JCI127471","volume":"129","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P (2019a) cGAS\/STING axis mediates a topoisomerase II inhibitor\u2013induced tumor immunogenicity. J Clin Invest 129(11):4850\u20134862","journal-title":"J Clin Invest"},{"issue":"11","key":"2186_CR103","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1172\/JCI127471","volume":"129","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P (2019b) cGAS\/STING axis and Topo II inhibitors. J Clin Invest 129(11):4850\u20134862","journal-title":"J Clin Invest"},{"issue":"1","key":"2186_CR104","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13659-023-00392-1","volume":"13","author":"M Wang","year":"2023","unstructured":"Wang M, Liang L, Wang R, Jia S, Xu C, Wang Y, Luo M, Lin Q, Yang M, Zhou H, Liu D (2023) Narciclasine as a topoisomerase I inhibitor. Nat Prod Bioprospect 13(1):27","journal-title":"Nat Prod Bioprospect"},{"issue":"2","key":"2186_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020178","volume":"16","author":"CA Wilkins","year":"2024","unstructured":"Wilkins CA, Hamman H, Hamman JH, Steenekamp JH (2024) Fixed-dose combination formulations in solid oral drug therapy. Pharmaceutics Basel 16(2):178","journal-title":"Pharmaceutics Basel"},{"issue":"1","key":"2186_CR106","doi-asserted-by":"publisher","first-page":"18882","DOI":"10.1038\/s41598-019-54796-6","volume":"9","author":"HC Wise","year":"2019","unstructured":"Wise HC, Iyer GV, Moore K, Temkin SM, Gordon S, Aghajanian C, Grisham RN (2019) DNA-PK inhibitor with Topo II inhibitors. Sci Rep 9(1):18882","journal-title":"Sci Rep"},{"issue":"38","key":"2186_CR107","doi-asserted-by":"publisher","first-page":"16631","DOI":"10.1002\/anie.202006089","volume":"59","author":"K Xiong","year":"2020","unstructured":"Xiong K, Qian C, Yuan Y, Wei L, Liao X, He L, Rees TW, Chen Y, Wan J, Ji L, Chao H (2020) Ruthenium complexes as dual Topo I\/II inhibitors. Angew Chem Int Ed Engl 59(38):16631\u201316637","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"2186_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101456","volume":"16","author":"PA Yakkala","year":"2023","unstructured":"Yakkala PA, Penumallu NR, Shafi S, Kamal A (2023) Prospects of topoisomerase inhibitors as promising anti-cancer agents. Pharmaceuticals Basel 16(10):1456","journal-title":"Pharmaceuticals Basel"},{"issue":"1","key":"2186_CR109","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11033-023-09055-3","volume":"51","author":"S Yanar","year":"2024","unstructured":"Yanar S, Kanli A, Kasap M, Bal Albayrak MG, Eskiler GG, Ozkan AD (2024) NSAID\u2013topotecan synergy in lung cancer. Mol Biol Rep 51(1):145","journal-title":"Mol Biol Rep"},{"issue":"19","key":"2186_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194568","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li Q, Huang Z, Li B, Nice EC, Huang C, Wei L, Zou B (2022) Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers Basel 14(19):4568","journal-title":"Cancers Basel"},{"key":"2186_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103131","volume":"91","author":"DC Zhou","year":"2019","unstructured":"Zhou DC, Lu YT, Mai YW, Zhang C, Xia J, Yao PF, Wang HG, Huang SL, Huang ZS (2019) Perimidine o-quinone catalytic inhibitors. Bioorg Chem 91:103131","journal-title":"Bioorg Chem"},{"issue":"14","key":"2186_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25143180","volume":"25","author":"W Zhou","year":"2020","unstructured":"Zhou W, Zhang W, Peng Y, Jiang ZH, Zhang L, Du Z (2020) Benzimidazole-chalcone hybrids as catalytic Topo II inhibitors. Molecules 25(14):3180","journal-title":"Molecules"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02186-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02186-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02186-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:02:58Z","timestamp":1778860978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02186-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":112,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02186-6","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable as the study does not involve any human participants or animal work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Authors declare the use of ChatGPT version 5.0, GPT Model 5 has been used during preparation of this manuscript purely for the purpose of language editing and improvement of readability. Thereafter all the authors read the final version of this manuscript and take full responsibility of technicalities, statements and data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Usage of generative AI"}}]}}